French trial opens in diabetes-diet drug scandal
Jacques Servier, center, founder of Servier Laboratories, sits with his lawyers during the opening of the trial at Nanterre's court house, outside Paris, Monday, May 14, 2012. A French court has opened the first of trials over a drug for diabetes commonly used to lose weight and suspected of killing at least 500 people. The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine, benfluorex _ removed from the market in 2009 after being found to thicken heart valves. (AP Photo/Michel Euler)
(AP) -- The first French trial has begun over a diabetes drug that was also used to lose weight and is suspected in the deaths of at least 500 people.
The pharmaceutical group Servier is suspected of "aggravated deception" for hiding the fact that the drug known as Mediator contained an amphetamine called benfluorex - which was taken off the market in 2009 after being found to thicken heart valves.
However, another investigation is underway and lawyers for Servier were arguing Monday against holding the current trial claiming that the laboratory could be judged twice on the same grounds.
The nature of benfluorex was allegedly hidden to obtain approval for the drug, first marketed in 1976. So far, charges have been filed against seven people, including drugmaker chief Jacques Servier.
©2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
Diabetes drug may have killed 500 in France: authorities
Nov 16, 2010 |
not rated yet |
0
-
'Fen-phen' derived drug responsible for thousands of hospitalizations and deaths in France
Feb 09, 2012 |
not rated yet |
0
-
Volunteer loses digits after drug trial
Jun 26, 2006 |
not rated yet |
0
-
Drugmaker pulls painkillers from US market over heart risks
Nov 19, 2010 |
not rated yet |
0
-
Britain to update its drug trial rules
Aug 03, 2006 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
13 hours ago
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
10 minutes ago |
not rated yet |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
22 hours ago |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Succesful results in developing oral vaccine against diarrhea
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
Medications
May 22, 2013 |
not rated yet |
0
When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs
Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...
Diabetes' genetic underpinnings can vary based on ethnic background, studies say
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
Flu vaccine also linked to narcolepsy in adults, study reports
Finnish researchers unveiled new data Thursday to link the Pandemrix flu vaccine to a higher risk of the sleeping disorder narcolepsy in adults.
Farm bill: Senate rejects GMO labeling amendment
The Senate has overwhelmingly rejected an amendment allowing states to require labeling of genetically modified foods.
Second child contracts polio in Pakistan's Waziristan
A second child has contracted polio in a restive Pakistani tribal region near the Afghan border after the Taliban banned vaccinations there nearly a year ago, a UN official said Thursday.
McDonald's can't shake criticism about nutrition
(AP)—McDonald's once again faced criticism that it's a purveyor of junk food that markets to children at its annual shareholder meeting Thursday.
